Naloxone Accord (Naloxone Hydrochloride)

Naloxone works by competitively binding to mu, kappa and delta opioid receptors in the central nervous system. By occupying these receptors without activating them, it displaces opioid agonists and blocks their effects, quickly restoring normal respiratory drive and central nervous system activity.

The exact dose and repeat dosing schedule are determined by the prescribing clinician based on the severity of the overdose, the patient’s response, and the specific opioid involved. Healthcare professionals follow local protocols and clinical judgment to decide the appropriate amount.

Data on naloxone use during pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should evaluate each case individually and consider alternative therapies when appropriate.

To order Naloxone Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and necessary import documentation.

Naloxone is the most widely used opioid antagonist because of its rapid onset and short duration, which allows for quick reversal while minimizing prolonged blockade. Alternatives such as nalmefene have a longer half‑life but are less commonly used in acute emergency settings. Naloxone’s established safety profile and availability make it the preferred choice for immediate overdose treatment.

Naloxone Accord should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If the product reaches room temperature for a short period, it may still be used, but it should be returned to refrigerated conditions promptly.

Naloxone Accord is supplied as an injectable solution for intravenous (IV) administration. In emergency situations, a healthcare professional injects the prescribed amount directly into a vein, monitors the patient’s response, and may repeat the dose if respiratory depression recurs.

The most serious risks include precipitating acute opioid withdrawal, which can cause severe agitation, pain, hypertension, and cardiac arrhythmias. Rarely, anaphylactic reactions may occur. Patients should be closely monitored for these events, and supportive care should be provided as needed.

Naloxone Accord should not be used in individuals with a known hypersensitivity to naloxone or any component of the formulation. It is also contraindicated in patients where opioid reversal is not indicated, such as those receiving opioid therapy for chronic pain without signs of overdose.